A Letter to Our Customers
Dear Valued Customer,
Boehringer Ingelheim has reached an agreement to sell Newport Laboratories, which manufactures custom-made vaccines for swine and cattle, to Vaxxinova.
By prioritizing our investments and focusing on key brands in our livestock portfolios, we believe we can deliver the greatest value to customers and ensure long-term growth and success in a dynamic and evolving business environment.
We believe that Vaxxinova will more fully realize the potential of Newport Laboratories, in Worthington, Minnesota. Vaxxinova US (previously known as Epitopix), is already active in Siderophore Receptors and Porins (SRP®) and autogenous vaccines in livestock. With this acquisition, Vaxxinova and Newport will be able to offer a more complete portfolio of products and services to livestock customers.
Vaxxinova and its predecessors have been in the livestock vaccine and diagnostics business since the 1950s. Their products and services, including autogenous and licensed vaccines and diagnostic services, are available in dozens of countries. The company’s focus is on production animals, including poultry, cattle, swine and aqua.
The companies expect to complete the transaction in the near future. We look forward to working collaboratively with the Newport Laboratories team and Vaxxinova to ensure a smooth transition for our customers and business partners.